PMV PHARMACEUTICALS, INC. (PMVP) Current Ratio
- Current ratio · latest quarter: Value 7.70×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.70× | Current assets / current liabilities. $81.41M ÷ $10.57M ≈ 7.70× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 81.41M USD | Assets, Current |
| Current obligations | 10.57M USD | Liabilities, Current |
| Cash and equivalents | 12.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 66.96M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $81.41M | $10.57M | $12.47M | $66.96M | (m) | (m) | $2.02M | (m) | 7.70× |
| 2026-03-31 | $95.78M | $8.60M | $39.13M | $54.42M | (m) | (m) | $1.63M | (m) | 11.14× |
| 2025-12-31 | $115.23M | $11.41M | $37.98M | $74.96M | (m) | (m) | $3.15M | (m) | 10.09× |
| 2025-09-30 | $132.45M | $12.30M | $36.34M | $92.91M | (m) | (m) | $3.40M | (m) | 10.76× |
| 2025-06-30 | $145.31M | $11.61M | $44.13M | $98.15M | (m) | (m) | $2.60M | (m) | 12.52× |
| 2025-03-31 | $163.50M | $9.76M | $51.34M | $109.05M | (m) | (m) | $3.59M | (m) | 16.75× |
| 2024-12-31 | $175.66M | $14.37M | $40.88M | $128.58M | (m) | (m) | $6.58M | (m) | 12.22× |
| 2024-09-30 | $189.62M | $13.56M | $48.81M | $134.03M | (m) | (m) | $2.06M | (m) | 13.98× |
| 2024-06-30 | $218.79M | $11.38M | $48.53M | $164.39M | (m) | (m) | $4.53M | (m) | 19.22× |
| 2024-03-31 | $202.46M | $12.06M | $47.65M | $150.28M | (m) | (m) | $859.00K | (m) | 16.79× |
| 2023-12-31 | $207.41M | $14.03M | $37.71M | $165.35M | (m) | (m) | $3.24M | (m) | 14.78× |
| 2023-09-30 | $205.30M | $10.72M | $52.06M | $149.86M | (m) | (m) | $1.68M | (m) | 19.16× |
| 2023-06-30 | $190.41M | $11.45M | $68.21M | $118.88M | (m) | (m) | $3.49M | (m) | 16.63× |
| 2023-03-31 | $233.28M | $10.59M | $142.94M | $86.49M | (m) | (m) | $1.77M | (m) | 22.03× |
| 2022-12-31 | $247.01M | $10.83M | $108.30M | $132.76M | (m) | (m) | $3.00M | (m) | 22.80× |
| 2022-09-30 | $265.18M | $11.66M | $99.85M | $159.01M | (m) | (m) | $4.83M | (m) | 22.75× |
| 2022-06-30 | $281.87M | $11.38M | $87.09M | $190.34M | (m) | (m) | $3.35M | (m) | 24.76× |
| 2022-03-31 | $288.04M | $11.69M | $115.77M | $167.22M | (m) | (m) | $4.86M | (m) | 24.65× |
| 2021-12-31 | $301.29M | $12.22M | $172.47M | $124.70M | (m) | (m) | $3.19M | (m) | 24.66× |
| 2021-09-30 | $313.56M | $8.56M | $176.64M | $131.01M | (m) | (m) | $1.28M | (m) | 36.62× |
| 2021-06-30 | $323.08M | $7.50M | $189.42M | $128.93M | (m) | (m) | $2.37M | (m) | 43.05× |
| 2021-03-31 | $334.95M | $5.80M | $208.78M | $122.71M | (m) | (m) | $1.25M | (m) | 57.79× |
| 2020-12-31 | $364.76M | $6.41M | $361.42M | (m) | (m) | (m) | $1.61M | (m) | 56.90× |
| 2020-09-30 | $373.67M | $5.48M | $373.15M | (m) | (m) | (m) | $548.00K | (m) | 68.24× |
| 2019-12-31 | $102.09M | $4.52M | $73.28M | $28.21M | (m) | (m) | $2.84M | (m) | 22.57× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |